Esaote has received FDA clearance for its MyLab A50 and MyLab A70 ultrasound systems, expanding the company's footprint in the U.S. diagnostic imaging market.

The Genoa, Italy- and Fishers, Indiana-based company first introduced the A-series systems to international audiences, and the latest regulatory approval paves the way for commercial distribution in the United States.

Both the A50 and A70 are compact, battery-operated systems intended to support a variety of clinical workflows, from basic diagnostic procedures to more advanced imaging. Esaote describes the platforms as designed for mobility, with configurations aimed at broad usability across different healthcare environments.
“The new A-series emphasizes user experience with a diverse range of interface options, including both a conventional and touch control panel,” said Thomas Will, director of ultrasound sales at Esaote North America. “The devices boast an intuitive, easy-to-clean design that allows clinicians to operate efficiently and confidently.”

The systems include tools for liver elastography and attenuation imaging, and support cardiology functions such as strain analysis for multiparametric evaluations. Esaote says both models incorporate artificial intelligence to assist with imaging precision and diagnostic workflow.

The FDA clearance aligns with the company’s broader product strategy focused on modular, flexible ultrasound systems that can adapt to both point-of-care and specialty clinical needs.

Esaote, a long-standing player in the diagnostic imaging space, continues to update its portfolio as part of a brand refresh aimed at integrating newer technologies and addressing evolving healthcare demands.

U.S. Healthcare Homepage